SOURCE: Chiesi USA, Inc.

Chiesi USA, Inc.

May 09, 2016 07:00 ET

Chiesi to Acquire 3 Hospital Products - Kengreal®, Cleviprex®, Argatroban for Injection

PARMA, ITALY--(Marketwired - May 09, 2016) -  Chiesi USA, Inc. and Chiesi Farmaceutici S.p.A., Chiesi USA's parent company, announced today that the companies have agreed to acquire worldwide rights of The Medicines Company to Kengreal® (cangrelor) and Cleviprex® (clevidipine), as well as rights to Argatroban for Injection, 50 mg per 50 mL. All three products are cardiovascular products for use in the hospital setting and all three are approved for sale in the U.S.

"Chiesi Group is fully committed to the continued success of our U.S. affiliate, and we will continue to provide support for the acquisition of marketed products that fit our profile, as well as ongoing investment in research and development," said Ugo DiFrancesco, CEO of Chiesi Farmaceutici S.p.A., Chiesi USA's parent company.

"Chiesi has an 80-plus year history of securing our future by investing in the well-being of patients who need us," DiFrancesco said, "and the U.S. is a significant contributor to our vision for that bright future."

Ken McBean, President and Chief Executive Officer of Chiesi USA, said, "The acquisition of all three products is a strategic fit for us, as we expand our product portfolio to become a recognized leader in the hospital and adjacent specialties. We are committed to delivering products that meet the needs of providers and enhance care for patients in those settings."

The transaction is expected to close in the third quarter of 2016 and is subject to customary closing conditions, including the expiration or termination of the waiting period under the Hart Scott Rodino Antitrust Improvements Act.

Chiesi Farmaceutici

Headquartered in Parma, Italy Chiesi Farmaceutici is an international research-focused Healthcare group, with over 80 years of experience in the pharmaceutical industry. Chiesi researches, develops and markets innovative drugs in the respiratory therapeutics, specialist medicine and rare diseases areas. Its R&D centers in Parma (Italy), Paris (France), Cary (USA), Chippenham (UK) and the R&D team of the acquired Danish company Zymenex, integrate their efforts to advance Chiesi's pre-clinical, clinical and registration programs. Chiesi employs over 4,500 people, 560 of whom are solely dedicated to Research and Development activities.

For more information, please visit the website www.chiesi.com.

Chiesi USA, Inc.

Chiesi USA, Inc., headquartered in Cary, N.C., is a specialty pharmaceutical company focused on commercializing products for the hospital and adjacent specialty markets. Key elements of the Company's strategy are to focus its commercial and development efforts in the hospital and adjacent specialty product sector within the U.S. pharmaceutical marketplace; continue to seek opportunities to acquire companies, marketed or registration-stage products and late-stage development products that fit within the Company's focus areas; and generate revenues by marketing approved generic products through the Company's wholly-owned subsidiary, Aristos Pharmaceuticals, Inc. Chiesi USA, Inc. is a wholly-owned subsidiary of Chiesi Farmaceutici S.p.A. For more information, visit www.chiesiusa.com.

PP-G-0003 V2.0

Contact Information

  • Contacts:

    Valentina Biagini
    Group Communication Manager

    Tel +39 348 7693 623
    Email v.biagini@chiesi.com